Antibacterial and antiproliferative activities of plumericin, an iridoid isolated from Momordica charantia vine

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Saengsai, Jutamas ^a   Kongtunjanphuk, Sumonthip ^b   Yoswatthana, Nuttawan ^a   Kummalue, Tanawan ^c   Jiratchariyakul, Weena ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KING MONGKUT'S UNIVERSITY OF TECHNOLOGY NORTH BANGKOK   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLOXACILLIN; IRIDOID; LACTONE DERIVATIVE; MOMORDICA CHARANTIA EXTRACT; PLUMERICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BACILLUS SUBTILIS; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; ENTEROCOCCUS FAECALIS; G2 PHASE CELL CYCLE CHECKPOINT; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; K562 CELL LINE; LEUKEMIA CELL; M PHASE CELL CYCLE CHECKPOINT; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOMORDICA CHARANTIA; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTUM YIELD; SOLID PHASE EXTRACTION; SUPERCRITICAL FLUID EXTRACTION; ULTRAVIOLET SPECTROSCOPY;

EID: 84928539717     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/823178     Document Type: Article

References (45)

1. G. V. Satyawati, A. K. Gupta, and N. Tandon, Medicinal Plants of India, Indian Council ofMedical Research, New Delhi, India, 1987.
2. E. Basch, S. Gabardi, and C. Ulbricht, "Bittermelon (Momordica charantia): a review of efficacy and safety, " American Journal of Health-System Pharmacy, vol. 60, no. 4, pp. 356-359, 2003.
3. M. Gupta, S. Sharma, A. K. Gautam, and R. Bhadauria, "Momordica charantia linn. (Karela): nature's silent healer, " International Journal of Pharmaceutical Sciences Review and Research, vol. 11, no. 1, pp. 32-37, 2011.
4. J. T. Efird, Y. M. Choi, S. W. Davies, S. Mehra, E. J. Anderson, and L. A. Katunga, "Potential for improved glycemic control with dietaryMomordica charantia in patients with insulin resistance and pre-diabetes, " International Journal of Environmental Research and Public Health, vol. 11, no. 2, pp. 2328-2345, 2014.
5. E. F. Fang and T. B. Ng, "Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, Anti-HIV, and antitumor properties, " Current Molecular Medicine, vol. 11, no. 5, pp. 417-436, 2011.
6. P. Nerurkar and R. B. Ray, "Bitter melon: antagonist to cancer, " Pharmaceutical Research, vol. 27, no. 6, pp. 1049-1053, 2010.
7. J. K. Grover and S. P. Yadav, "Pharmacological actions and potential uses of Momordica charantia: a review, " Journal of Ethnopharmacology, vol. 93, no. 1, pp. 123-132, 2004.
8. M. R. Khan and A. D. Omoloso, "Momordica charantia and Allium sativum: broad spectrum antibacterial activity, " Korean Journal of Pharmacognosy, vol. 29, no. 3, pp. 155-158, 1998.
9. R. E. Omoregbe, O. M. Ikuebe, and I. G. Ihimire, "Antimicrobial activity of some medicinal plants extracts on Escherichia coli, Salmonella paratyphi and Shigella dysenteriae, " African Journal of Medicine and Medical Sciences, vol. 25, no. 4, pp. 373-375, 1996.
10. A. D. Frame, E. Rios-Olivares, L. de Jesús, D. Ortiz, J. Pagán, and S. Méndez, "Plants from Puerto Rico with anti-Mycobacterium tuberculosis properties, " Puerto RicoHealth Sciences Journal, vol. 17, no. 3, pp. 243-252, 1998.
11. R. C. Agrawal and T. Beohar, "Chemopreventive and anticarcinogenic effects ofMomordica charantia extract, " Asian Pacific Journal of Cancer Prevention, vol. 11, no. 2, pp. 371-375, 2010.
12. H. M. dos Santos Jr., D. F. Oliveira, D. A. De Carvalho et al., "Evaluation of native and exotic Brazilian plants for anticancer activity, " Journal ofNaturalMedicines, vol. 64, no. 2, pp. 231-238, 2010.
13. P. Pitchakarn, K. Ogawa, S. Suzuki et al., "Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and invivo, " Cancer Science, vol. 101, no. 10, pp. 2234-2240, 2010.
14. P. Pitchakarn, S. Ohnuma, K. Pintha, W. Pompimon, S. V. Ambudkar, and P. Limtrakul, "Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediatedmultidrug resistance, " Journal of Nutritional Biochemistry, vol. 23, no. 1, pp. 76-84, 2012.
15. P. Pitchakarn, S. Suzuki, K. Ogawa et al., "Kuguacin J, a triterpeniod from Momordica charantia leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3, " Food and Chemical Toxicology, vol. 50, no. 3-4, pp. 840-847, 2012.
16. J. Zhang, Y. Huang, T. Kikuchi et al., "Cucurbitane triterpenoids from the leaves of Momordica charantia, and their cancer chemopreventive effects and cytotoxicities, " Chemistry and Biodiversity, vol. 9, no. 2, pp. 428-440, 2012.
17. W. Waiyaput, S. Payungporn, J. Issara-Amphorn, and N. T.-T. Panjaworayan, "Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells, " BMC Complementary and Alternative Medicine, vol. 12, article 246, 2012.
18. H.-Y. Hsu, J.-H. Lin, C.-J. Li et al., "Antimigratory effects of the methanol extract from Momordica charantia on human lung adenocarcinoma CL1 cells, " Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 819632, 12 pages, 2012.
19. R. Bruni, A. Guerrini, S. Scalia, C. Romagnoli, and G. Sacchetti, "Rapid techniques for the extraction of vitamin E isomers from Amaranthus caudatus seeds: ultrasonic and supercritical fluid extraction, " Phytochemical Analysis, vol. 13, no. 5, pp. 257-261, 2002.
20. L. Nahar and S. D. Sarker, "Supercritical fluid extraction, " in Natural Products Isolation, S. D. Sarker, A. Latif, and A. I. Gray, Eds., pp. 47-76, Humana Press, Totowa, NJ, USA, 2nd edition, 2006.
21. Sepiatec GmbH, Sepbox 2D Manual, Sepiatec GmbH, Berlin, Germany, 2012.
22. M. Bhandari and A. Bhandari, "Sepbox technique in natural products, " Journal of Young Pharmacists, vol. 3, no. 3, pp. 226-231, 2011.
23. J. H. Ortez, "Disk diffusion testing, " inManual of Antimicrobial Susceptibility Testing, M. B. Coyle, Ed., pp. 39-52, American Society for Microbiology, Washington, DC, USA, 2005.
24. A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, "Antibiotic susceptibility testing by a standardized single disk method, " American Journal of Clinical Pathology, vol. 45, no. 4, pp. 493-496, 1966.
25. J. H. Jorgensen and J. D. Turnidge, "Antibacterial susceptibility test: dilution and disk diffusionmethods, " inManual of Clinical Microbiology, P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller, Eds., pp. 1152-1172, American Society for Microbiology, Washington, DC, USA, 9th edition, 2007.
26. J. H. Jorgensen and M. J. Ferraro, "Antimicrobial susceptibility testing: a review of general principles and contemporary practices, " Clinical Infectious Diseases, vol. 49, no. 11, pp. 1749-1755, 2009.
27. I. D. Rankin, "MIC testing, " inManual of Antimicrobial Susceptibility Testing, M. B. Coyle, Ed., pp. 53-62, American Society for Microbiology, Washington, DC, USA, 2005.
28. Y. U-Praty, T. Pratumrat, W. Jiratchariyakul, and T. Kummalue, "Antiproliferative activity of Erycibe elliptilimba against human leukemic cancer cell lines, " Journal ofMedicinal Plants Research, vol. 6, no. 13, pp. 2606-2613, 2010.
29. T. Kummalue, M. Suntiparpluacha, and W. Jiratchariyakul, "Antiproliferative activity of combination ofThai herbal remedy and chemotherapeutic agents on human cancer cell lines, " Journal of Medicinal Plants Research, vol. 6, no. 2, pp. 200-205, 2012.
30. H. Mueller, M. U. Kassack, and M. Wiese, "Comparison of the usefulness of the MTT, ATP, and Calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines, " Journal of Biomolecular Screening, vol. 9, no. 6, pp. 506-515, 2004.
31. P. Skehan, R. Storeng, D. Scudiero et al., "New colorimetric cytotoxicity assay for anticancer-drug screening, " Journal of the National Cancer Institute, vol. 82, no. 13, pp. 1107-1112, 1990.
32. Y.-L. Hsu, P.-L. Kuo, L.-C. Chiang, and C.-C. Lin, "Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer A549 cells, " Clinical and Experimental Pharmacology and Physiology, vol. 31, no. 7, pp. 414-418, 2004.
33. T. Kummalue, P. O-charoenrat, W. Jiratchariyakul et al., "Antiproliferative effect of Erycibe elliptilimba on human breast cancer cell lines, " Journal of Ethnopharmacology, vol. 110, no. 3, pp. 439-443, 2007.
34. F. Abe, R. F. Chen, and T. Yamauchi, "Minor iridoids from the roots of Plumeria acutifolia, " Chemical and Pharmaceutical Bulletin, vol. 36, no. 8, pp. 2784-2789, 1988.
35. J. E. Little and D. B. Johnstone, "Plumericin; an antimicrobial agent from Plumeria multiflora, " Archives of biochemistry, vol. 30, no. 2, pp. 445-452, 1951.
36. L. B. S. Kardono, S. Tsauri, K. Padmawinata, J. M. Pezzuto, and A. D. Kinghorn, "Cytotoxic constituents of the bark of Plumeria rubra collected in Indonesia, " Journal of Natural Products, vol. 53, no. 6, pp. 1447-1455, 1990.
37. M. O. Hamburger, G. A. Cordell, and N. Ruangrungsi, "Traditional medicinal plants of Thailand XVII. Biologically active constituents of Plumeria rubra, " Journal of Ethnopharmacology, vol. 33, no. 3, pp. 289-292, 1991.
38. M. S. Abdel-Kader, J. Wisse, R. Evans, H. Van der Werff, and D. G. I. Kingston, "Bioactive iridoids and a new lignan from Allamanda cathartica and Himatanthus fallax from the suriname rainforest, " Journal of Natural Products, vol. 60, no. 12, pp. 1294-1297, 1997.
39. V. S. Bolzani, M. C. Young, M. Furlan et al., "Search for antifungal and anticancer compounds from native plant species ofCerrado andAtlantic Forest, "Anais daAcademiaBrasileirade Ciências, vol. 71, no. 2, pp. 181-187, 1999.
40. G. M. Kuigoua, S. F. Kouam, B. T. Ngadjui et al., "Minor secondary metabolic products from the stem bark of Plumeria rubra Linn. Displaying antimicrobial activities, " Planta Medica, vol. 76, no. 6, pp. 620-625, 2010.
41. V. Kuete and T. Efferth, "Pharmacogenomics of Cameroonian traditional herbal medicine for cancer therapy, " Journal of Ethnopharmacology, vol. 137, no. 1, pp. 752-766, 2011.
42. U. Sharma, D. Singh, P. Kumar, M. P. Dobhal, and S. Singh, "Antiparasitic activity of plumericin and isoplumericin isolated from Plumeria bicolor against Leishmania donovani, " Indian Journal of Medical Research, vol. 134, no. 11, pp. 709-716, 2011.
43. D. Singh, U. Sharma, P. Kumar, Y. K. Gupta, M. P. Dobhal, and S. Singh, "Antifungal activity of plumericin and isoplumericin, " Natural Product Communications, vol. 6, no. 11, pp. 1567-1568, 2011.
44. P. Kumar, A. Singh, U. Sharma, D. Singh, M. P. Dobhal, and S. Singh, "Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis, " Pulmonary Pharmacology andTherapeutics, vol. 26, no. 3, pp. 332-335, 2013.
45. N. Fakhrudin, B. Waltenberger, M. Cabaravdic et al., "Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo, " British Journal of Pharmacology, vol. 171, no. 7, pp. 1676-1686, 2014.